This inventor holds 1 USPTO granted patent and 1 published patent application and 1 EPO patent. Top assignee: Merck Sharp + Dohme Corp.. Active years: 2021.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2021
Title: Gregory L Adams: Innovator in Pharmaceutical Compounds
Introduction
Gregory L Adams is a notable inventor based in Vincentown, NJ (US). He has made significant contributions to the field of pharmaceuticals, particularly in the development of compounds that target specific health conditions.
Latest Patents
Adams holds a patent for "Substituted tetrahydroisoquinoline compounds useful as GPR120 agonists." This invention relates to compounds represented by a specific formula and their pharmaceutically acceptable salts. These compounds are designed to treat or prevent various conditions, including diabetes, hyperlipidemia, obesity, NASH, and inflammation-related disorders. The compounds function as agonists of the G-protein coupled receptor GPR120, and the patent also includes pharmaceutical compositions and methods of treatment.
Career Highlights
Gregory L Adams is associated with Merck Sharp & Dohme Corporation, a leading company in the pharmaceutical industry. His work focuses on innovative solutions to pressing health issues, showcasing his commitment to improving patient outcomes through scientific advancements.
Collaborations
Adams has collaborated with notable colleagues, including Jason M Cox and John S Debenham, contributing to a dynamic research environment that fosters innovation and discovery.
Conclusion
Gregory L Adams exemplifies the spirit of innovation in the pharmaceutical sector, with his patented compounds offering potential solutions for various health challenges. His work continues to impact the field positively.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile